30 closest matches · ranked by relevance
Primary Sclerosing Cholangitis
Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants
Primary Sclerosing Cholangitis
Primary: Number of Participants With Treatment Emergent Adverse Events — 21; 10; 16; 15 Participants
Primary Sclerosing Cholangitis (PSC)
Primary: Change From Baseline in MQC on Liver Biopsy at Week 96 — -0.5; 0.5; 0.0 percentage of MQC
Primary Sclerosing Cholangitis
Primary: Change in Serum Alkaline Phosphatase (SAP) — 3 Participants — p=.03
Primary Sclerosing Cholangitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase — 81.8; 70.0; 100.0 percentage of participants
Primary Sclerosing Cholangitis (PSC)
Primary: DB Phase: Change From Baseline In Serum Alkaline Phosphatase (ALP) — -105.05; -110.19; -26.76 U/L — p=0.0434
Primary Sclerosing Cholangitis
Primary: Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis — 25.6; -9.8; -0.6 International units/Liter — p=0.434
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
Sclerosing Cholangitis
Primary: Adverse Event Frequency — 8 Participants
Primary Sclerosing Cholangitis
Primary: Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels. — 3 Participants
Primary Sclerosing Cholangitis
Primary: Change From Baseline in Alkaline Phosphatase Following 12 Weeks of Treatment — -117; -49; -62; -36 U/L
Pruritus
Primary: Change From Baseline in the Worst Itch Numeric Rating Scale (WI-NRS) Score up to Week 6 — -2.20; -1.75 scores on a scale — p=0.4577
Primary Sclerosing Cholangitis (PSC)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 2; 1 participant
Primary Biliary Cholangitis · Liver Stiffness
Primary: Change in ALP at Week 24 Compared to Baseline — 0.89; 0.84; 1.03 ratio — p=0.0206
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
Biliary Atresia
Primary: The Percentage of Patients With Serum Total Bilirubin <1.5 mg/dL and With Native Liver at 6 Months After Portoenterostomy — 58.6; 48.6 percentage of participants — p=0.43
Primary Sclerosing Cholangitis
Primary: Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP) — -4.5 percentage change in ALP
Biliary Atresia
Primary: Number of Patients With Biliary Atresia (BA) Achieving Total Serum Bile Acids Less Than or Equal to 10 *U*Mol/L Within 24 Weeks of Kasai Portoenterostomy (KP) — 0…
Disorders of the Pancreas and Biliary Tree
Primary: Successful Procedure Completion — 70; 5 participants
Primary Biliary Cholangitis
Primary: Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline — 45.2; 46.4; 11.1…
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Primary Biliary Cirrhosis
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 — -26.06; -33.38; -41.42 percentage change from baseline — p== 0.2242
Cholangiocarcinoma
Primary: Median Progression Free Survival (PFS) — 6 months
Biliary Tract Diseases
Primary: Procedural Success as Defined by: 1. Ability to Visualize Stricture & Obtain Biopsy of Lesion Adequate for Histological Examination in Suspected Malignancy Cases or 2…
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Primary Sclerosing Cholangitis · Biliary Atresia
Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Primary Biliary Cirrhosis
Primary: Change in Serum Alkaline Phosphatase Levels. — -57.3 U/L — p=0.001
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3…